Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe

This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway

Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol

Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.

Zydus launches Bemdac to treat LDL-Cholesterol

It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins

Study reveals over 80 % newly diagnosed diabetic patients have at least one cholesterol abnormality

The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted

Evonik expands production of plant-derived cholesterol in Germany

The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol

Amneal and mAbxience score FDA green light for two Denosumab biosimilars

Merck strikes historic deal with Trump admin to lower drug costs for Americans

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor